stockrowTango Therapeutics, Inc.
TNGX Healthcare Biotechnology
Tango Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.4 million, up 48.3% from fiscal 2024.
- Revenue
- −100.0%
- EPS
- −5.71%
- Free cash flow
- −4.58%
Quarter to June 2026, against a year earlier
Follow TNGX
Alert me
Tango Therapeutics, Inc. (TNGX) Revenue
Tango Therapeutics, Inc.'s revenue for fiscal 2025 was $62.4M, up 48.3% from $42.1M in fiscal 2024. Over the past ten years it has ranged from $7.7M (fiscal 2020) to $62.4M (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 3 consecutive fiscal years. Tango Therapeutics, Inc. ranks 118th of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $62.4M | 48.29% |
| FY2024 | $42.1M | 15.17% |
| FY2023 | $36.5M | 46.93% |
| FY2022 | $24.9M | (32.89%) |
| FY2021 | $37.0M | 383.83% |
| FY2020 | $7.7M | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Dec 2025 | $0.00 | — |
| Sep 2025 | $53.8M | 1,591.64% |
| Jun 2025 | $3.2M | (41.01%) |
| Mar 2025 | $5.4M | 31.00% |
| 17 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | $1.2B |
| IOVA Iovance Biotherapeutics, Inc. compare | $379.0M |
| ABCL AbCellera Biologics Inc. compare | $66.2M |
| TNGX Tango Therapeutics, Inc. | $62.4M |
| XENE Xenon Pharmaceuticals Inc. compare | $16.9M |
| RLAY Relay Therapeutics, Inc. compare | $11.0M |
| PBLS Parabilis Medicines, Inc. compare | — |
| EWTX Edgewise Therapeutics, Inc. compare | — |
| IRON Disc Medicine, Inc. compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on TNGX
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement